[CLSTR]
< Back to situations

We’ll email you as it develops, and you can follow the whole thread from day one.

[SITUATION] · [ACTIVE]

2 clusters · 2 sources · 29 days · First seen · Last updated

Categories: HEALTH

Multiple Myeloma treatment and incidence trends

Entities: t(11;14) translocation · International Myeloma Society · BCL2 inhibitors · Prof Nikhil C. Munshi · Multiple Myeloma

Overview

In early July 2026, health officials in Colombia reported an increase in multiple myeloma cases, noting that newer therapeutic options were beginning to improve patient outlooks despite the disease’s incurable status.

By the end of July, the International Myeloma Society’s annual meeting in Glasgow gathered thousands of clinicians and scientists to discuss the latest advances. Highlights included the identification of the t(11;14) translocation as a biomarker for BCL2‑inhibitor therapy, the expansion of blood‑based diagnostics, AI applications in treatment planning, and broader strategies for newly diagnosed and relapsed patients. Together, these reports illustrate a parallel trajectory of rising disease incidence in specific regions and accelerating progress in targeted, biomarker‑driven treatments worldwide.

Timeline

  1. 7 days ago

    [HEALTH] 2 sources
    Multiple Myeloma Advances Spotlighted at IMS Meeting in Glasgow

    A review highlights the t(11;14) translocation and BCL2‑inhibitors as targets in multiple myeloma, while the IMS meeting in Glasgow gathers experts to discuss new therapies and steps toward curing the disease.

  2. about 1 month ago

    [HEALTH] 2 sources
    Colombia sees rise in multiple myeloma cases, new treatments improve outlook

    Colombia, with one of the highest rates of multiple myeloma in Latin America, expects a 50 % case rise by 2040; new targeted therapies extend survival and improve disease control, though late diagnoses remain a

Sources

haematologica.org · imt.ie